Biotech, Alzheimer's, Finances
ProteoTech Raises $519K
Luke Timmerman 5/11/09
ProteoTech, a Kirkland, WA-based developer of neurology drugs, said it has raised $519,000 in a debt offering, according to a regulatory filing. The company, founded in 1996, is testing an oral pill called Exebryl-1 in clinical trials for mild to moderate Alzheimer’s disease, and has another drug in animal testing for Parkinson’s disease, according to its website. Chairman Alan Snow couldn’t be reached for comment.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
5/11/09 9:24 pm
[...] Finally, ProteoTech, a company we also profiled some time ago, said it has raised $519K in a debt offering, according to Xconomy. ProtetoTech is developing Exebryl-1, a component of Cat’s Claw, for mild to moderate Alzheimer’s disease. The company also has an earlier stage drug in development for Parkinson’s disease which is funded by the Michael J. Fox Foundation. [Xconomy] [...]